CASP1 and Sepsis: Broad-spectrum caspase inhibitors could also be evaluated, such as VX-166, which is active against caspase-1, caspase-3 and caspase-7, and has been proposed for the treatment of sepsis and endotoxic shock (Dhani et al., 2021; Di Salvo et al., 2019).